Fungal infections range in severity from common superficial problems affecting the skin and nails, to deeply invasive and disseminated infections, such as systemic candidiasis and pulmonary aspergillosis.
tions, combined with the reduced efficacy of the currently available drugs, highlights the need for new antifungal drugs with different modes of action and targets that are distinct from those traditionally used.
Myristoyl-CoA:protein N-myristoyltransferase (Nmt; EC 2.1.3.97) catalyzes the transfer of the fatty acid, myristate (C14 : 0), from myristoyl-CoA to the amino (N)-terminal glycine residue of a number of eukaryotic cellular and viral proteins. [6] [7] [8] Myristoylation is required for full expression of the biological function of these proteins, ensuring conformational stability and the ability to interact with membranes or the hydrophobic domains of other proteins. [9] [10] [11] Nmt performs this critical function in the eukaryotic cell and is essential for the in vitro viability of many species of fungi, including Candida albicans and Cryptococcus neoformans, which are both medically important. 12, 13) Furthermore, C. albicans with defective Nmt loses the ability to infect mice. 14) So far, studies aiming to create novel antifungal agents have described two classes of synthetic fungal Nmt inhibitors: the benzofurans and the benzothiazoles. The antifungal properties of the benzofurans have been well studied both in vitro and in vivo, but there is a paucity of information on the benzothiazoles. 15) We performed in silico and wet screening of approximately 3000000 commercially available small compounds in our laboratory. We identified 20 compounds with C. albicans Nmt (CaNmt) inhibitory activity, and among these, two compounds had the benzothiazole scaffold. Based on our screening results and information on the structure-activity relationship, we have synthesized the novel benzothiazole derivative FTR1335 (Fig. 1) .
16) The present study examined the properties of FTR1335 with the aim of developing it further as an antifungal drug.
MATERIALS AND METHODS

Chemicals and Reagents
cyclohexanecarboxamide, was synthesized at SSP Co., Ltd. (Chiba, Japan). Amphotericin-B (AMPH) and fluconazole (FLCZ) were purchased from Sigma-Aldrich (Tokyo, Japan) and Pfizer Pharmaceuticals Inc. (CT, U.S.A.), respectively. The PCR primers and the substrate peptides for Nmt assays were synthesized by Sigma-Aldrich. General laboratory chemicals were of analytical grade.
Expression and Purification of Recombinant Nmts The CaNmt coding gene was amplified by PCR from a C. albicans ATCC 90028 genomic library using the primers 5Ј-NNNNNNNNCATATGTCGGGAGATAACACAGGGA-ATAAATC-3Ј and 5Ј-NNNNNNGCGGCCGCTAATAAA-ACTACACCTATACCACTTGTTTGATCTTCG-3Ј, with the Advantage-HF PCR kit (Clontech, CA, U.S.A.). The PCR product was ligated to the Escherichia coli expression vector pET-15b (Novagen, WI, U.S.A.) between the Nde I and the BamH I sites, to obtain CaNmt protein with an N-terminal poly-histidine tag. Likewise, the human Nmt1 (HsNmt1) coding gene was amplified from human lymphocyte cDNA library using the primers 5Ј-NNNNNNCATATGGCGGAC-GAGAGTGAGACAGC-3Ј and 5Ј-NNNNNNCTCGAGTTA-TTGTAGCACCAGTCCAACCTTCTCTGC-3Ј, and ligated to pET-15b between the Nde I and the Xho I sites. The sequences of both expression vectors were confirmed using an ABI PRISM 310.
E. coli BL21(DE3) containing the CaNmt or HsNmt1 expression vector was grown at 37°C in medium containing 10 g/l trypton, 5 g/l yeast extract, 10 g/l NaCl and 100 mg/ml ampicillin until the absorbance at 600 nm reached 0.8, at which time isopropyl b-D-thiogalactopyranoside was added to a final concentration of 1 mM. The cultures were maintained at 28°C for a further 4 h and the bacteria were harvested by centrifugation. The bacteria were then suspended in PBS and disrupted by sonication. The lysate was clarified by centrifugation and the supernatant was applied to TALON metal-affinity resin (Clontech) to purify the poly-histidine tagged Nmt protein according to the manufacturer's protocol. The fraction containing the purified Nmt protein was dialyzed overnight against the Nmt reaction buffer (10 mM TrisHCl (pH 7.4), 1 mM DTT, 5 mM MgCl 2 and 0.1 mM EGTA).
Measurement of FTR1335 Inhibition of CaNmt and HsNmt1
An in vitro Nmt assay was performed as described by Towler et al. 17) and Masubuchi et al., 18) with slight modifications. The reaction was assembled to a final volume of 100 ml giving a final concentration of 10 mM Tris-HCl (pH 7.4), 1 mM DTT, 5 mM MgCl 2 , 0.1 mM EGTA, 0.01% Triton X-100, 0.5 mM peptide substrate (GLTISKLFRR-NH 2 for CaNmt and GNAASARR-NH 2 for HsNmt1) and 32 nM [ 3 H]-myristoyl-CoA (Amersham Biosciences, NJ, U.S.A.). The appropriate amounts of enzyme and FTR1335 were included at variable concentrations. After pre-incubation at 30°C for 10 min, the reaction was initiated by the addition of enzyme. After incubation at 30°C for 10 min, the reaction was terminated by the addition of 100 ml ice-cold methanol containing 2% tritonX-100 and 10% TCA. The reaction mixture was analyzed by HPLC under the conditions described previously 17) to quantify the [ 3 H]-myristoylated peptide reaction product. The inhibitory activity of FTR1335 was measured at each concentration. The quantity of [ 3 H]-myristoylated peptide in the reaction lacking FTR1335 was defined as the control (100%), and that without enzyme was defined as the background (0%). The effects of FTR1335 at each concentration were calculated as a percentage of the control. The 50% inhibitory concentration (IC 50 ) of FTR1335 was calculated by nonlinear regression analysis using the Prism 3.0 software package (GraphPad Software, San Diego, CA. U.S.A.). Assays were performed in triplicate and repeated at least twice.
Determination of the Mode of FTR1335 Inhibition by CaNmt
The mode by which FTR1335 was inhibited was determined using the methods described by Devadas et al. 19) The mode of inhibition with respect to peptide was evaluated by varying the concentration of the peptide substrate between 0.25 and 4 mM, and FTR1335 between 0 and 3 nM, at a fixed concentration of [ 3 H]-myristoyl-CoA of 8 nM. The mode of inhibition with respect to myristoyl-CoA was evaluated by varying the concentration of myristoyl-CoA between 2 and 16 nM, and FTR1335 between 0 and 3 nM, and fixing the concentration of the substrate peptide at 0.5 mM. The reaction times for each experiment were adjusted so that the amount of substrate which had undergone the reaction, did not exceed 15%. The product was quantitated as described above. Data were analyzed by nonlinear regression (MichaelisMenten) and linear regression of a double-reciprocal plot (Lineweaver-Burk) using the Prism 3.0 software package. Assays were performed in triplicate and repeated at least twice.
In Vitro Antifungal Activity The minimum inhibitory concentrations (MICs) of FTR1335, RO-09-4879, AMPH and FLCZ were determined using the National Committee for Clinical Laboratory Standards (NCCLS) broth-microdilution method M27-A2 20) for C. albicans, Candida krusei, Candida parapsilosis, Candida tropicalis, Candida glabrata and Cryptococcus neoformans, and method M38-A 21) for Aspergillus flavus, Aspergillus fumigatus, Trichophyton mentagrophaytes and Trichophyton rubrum. The Candida species and Cryptococcus neoformans were cultured at 35°C for 48 h, and the MICs were defined as the lowest concentration at which there was 80% inhibition of growth compared with the growth of a drug-free control. Aspergillus and Trichophyton species were cultured at 35°C for 48 h, and at 27°C for 72 h, respectively, and the MICs were defined as 50% inhibition of growth.
The Minimum Fungicidal Concentrations (MFCs) of FTR1335, RO-09-4879, AMPH and FLCZ against C. albicans ATCC 90028 were determined as described by Tawara et al. 22) After the MIC was measured, the microtiter plates were shaken and a 100 ml sample from each well of the microtiter plate was transferred to a single-reservoir plate containing SD agar. The plates were incubated for at least 72 h at 35°C. The MFC was defined as the minimum concentration of compound that resulted in growth of less than 2 CFU; this corresponds to the killing of Ͼ99% of the original inoculum.
RESULTS
Inhibitory Activities of FTR1335 for CaNmt and HsNmt1
The benzofurans and benzothiazoles are the only non-peptidic synthetic CaNmt inhibitors that have been reported to date. A novel benzothiazole CaNmt inhibitor that we recently synthesized was designated FTR1335. The inhibitory activity of compounds such as FTR1335 was assessed using [ 3 H]-myristoyl-CoA and the synthetic peptides as the enzyme substrates, and recombinant CaNmt and human Nmt1 (HsNmt1) prepared in E. coli. FTR1335 strongly inhibited the CaNmt reaction in a dose-dependent manner with an IC 50 of 0.49Ϯ0.04 nM and a Hill slope equal to 1.1 ( Fig. 2A) . Conversely, FTR1335 showed little dose-dependent inhibition of the HsNmt1 reaction with an IC 50 of 5400Ϯ260 nM and a Hill slope of 0.9 (Fig. 2B) , indicating excellent selectivity over 10000ϫ between 0.49 and 5400. A benzofuran derivative RO-09-4879, which was reported by Masubuchi et al., 18) also strongly inhibited the CaNmt reaction in our assay system, with an IC 50 of 3 nM, as Masubuchi reported.
Mode of CaNmt Inhibition by FTR1335
The Nmt enzyme has an ordered Bi-Bi reaction mechanism 23, 24) : it first binds to myristoyl-CoA, to cause conformational changes which then generate a second binding site for peptides. A ternary myristoyl-CoA: Nmt-peptide complex then forms, leading to catalysis and product release. When developing inhibitors of catalysis, it is important to understand how a particular compound inhibits the enzyme of interest. The mode of inhibition of CaNmt by FTR1335 was investigated using kinetic analysis ( Fig. 3 ; Table 1 ). The kinetics data were analyzed by nonlinear regression (Michaelis-Menten) and linear regression of a double-reciprocal plot (Lineweaver-Burk). The kinetic parameters of each FTR1335 concentration tested, calculated by non-linear regression (MichaelisMenten) are summarized in Table 1 . The V max with respect to the substrate peptide remained constant even when the concentration of FTR1335 was varied. Conversely, the K m with respect to myristoyl-CoA was constant when the concentration of FTR1335 was varied. These data demonstrate that FTR1335 was competitive with the substrate peptide and non-competitive with myristoyl-CoA.
In Vitro Antifungal Activities of FTR1335 The MICs of antifungal agents for various pathogenic fungi, including FTR1335, RO-09-4879 and the other antifungal agents, are shown in Table 2 . FTR1335 strongly inhibited many C. albicans isolates, including FLCZ-resistant isolates (IFM 47596, IFM 47597, IFM 47598, IFM 47601 and IFM 46909) and C. tropicalis (MIC 0.39-3.13 mM). The inhibition was equal to, or slightly stronger than, that produced by FLCZ, which is the most commonly used antifungal agent. FTR1335 had no activity in vitro against the other non-albicans Candida species, Aspergillus species, Trichophyton species and Cryptococcus neoformans. A benzofuran derivative RO-09-4879 was superior to FTR1335 in terms of antifungal activities and spectrum width. The MFCs (that is, the killing of Ͼ99% of the original inoculum) of FTR1335, RO-09-4879 and the other antifungal agents for C. albicans ATCC 90028 are shown in Table 3 . FTR1335 showed MFC value of 0.78 mM, which is slightly higher than that of RO-09-4879. AMPH showed more stronger fungicidal activity with MFC 0.20 mM. The MFC of FLCZ, which has only fungistatic activities, The parameters were calculated using the Prism 3.0 software package. Data represent the meansϮS.E.M. obtained from three similar measurements.
could not been determined. These data suggested that the antifungal activity of FTR1335 against this strain was fungicidal.
DISCUSSION
The drawbacks of the currently available antifungal drugs mean that the identification of new antifungal agents with novel modes of action is a priority. Nmt is considered to be a molecular target for the next generation of antifungal agents, in addition to elongation factors, GPI anchoring, calcineurin and so on. 25) FTR1335 is a novel benzothiazole derivative, which strongly inhibited CaNmt and weakly inhibited HsNmt1. This inhibition was dose-dependent with the Hill slope approximating 1, indicating one-to-one stoichiometry. Fungal Nmt inhibitors should be developed to avoid the toxicity that results from the inhibition of human Nmts. The myristoyl-CoA-binding sites of purified human Nmt and fungal Nmts are highly conserved, but their peptide-binding sites are divergent 26) ; therefore, a fungal inhibitor should target the enzyme at the peptide-binding site to avoid toxicity. The mode of inhibition of CaNmt by FTR1335 was investigated and kinetic studies revealed that it was competitive with the peptide-binding site, but non-competitive with the myristoyl-CoA-binding site. This indicates that FTR1335 acts at only the peptide-biding site of CaNmt with one-to-one stoichiometry, suggesting that FTR1335 is an appropriate lead compound for further development.
As shown in Table 4 , the Nmt amino acid residues possibly involved in interaction with substrate peptides as estimated by the crystal structure 27) are completely conserved between C. albicans and C. glabrata. Our results demon- 594 Vol. 28, No. 4 MICs were determined by the broth NCCLS microdilution method M27-A2 (Candida species and C. neoformans) and method M38-A (Aspergillus and Trichophyton species). The experiments were done in duplicate three times. One representative result is shown. V108  V100  V148  V115  V181  D110  D102  D150  D117  D183  D112  D104  N152  D119  D185  F115  F107  F155  F122  F188  F117  F109  F157  F124  F190  Y225  Y215  Y263  Y230  Y296  H227  H217  H265  H232  H298  P229  P219  P267  N234  S300  F240  F230  F278  F245  F311  Y256  Y246  N294  Y261  Y327  F339  F330  S378  S351  S405  D412  D413  D454  D456  D471  G413  G414  G455  G457  G472  L451  L451  L492  L491  Q496 Based on the study of crystral structure, 27) the amino acid residues in CaNmt, which interact with the substrate peptide analog, SC-58272 are identified. For other Nmts, the corresponding amino acids were determined by sequence alignment with GENETYX soft ware ver.6.1.0 (GENETYX, Tokyo, Japan). The following abbreviations are used: CgNmt: Candida glabrata Nmt, AfNmt: Aspergillus fumigatus Nmt, CnNmt: Cryptococcus neoformans Nmt. The amino acids different from CaNmt are highlighted in gray.
strate that FTR1335 exhibits strong antifungal activity in vitro against many C. albicans isolates including FLCZ-resistant isolates, but does not inhibit the growth of C. glabrata. It would be intriguing to examine if FTR1335 inhibits Nmt activity of C. glabrata. In addition, the nucleotide sequences of Nmt of Aspergillus fumigatus and Cryptococcus neoformans have been reported. The amino acid residues possibly responsible for the enzyme function are different from those of C. albicans, similar to human Nmt, which is not inhibited by FTR1335. In this context, further analyses of the effects of FTR1335 on Nmt of Aspergillus fumigatus and Cryptococcus neoformans may provide information on the mode of action of FTR1335. This might help development of effective derivatives. The results obtained in the MFC assay indicated that FTR1335 also has strong fungicidal activity against C. albicans, apparently reflecting the essential requirement for Nmt in fungi. The bovine serum albumin in the broth did not reduce the in vitro antifungal activity of FTR1335 (data not shown). This is a required property for compounds that are used in vivo, as it indicates that the protein-binding rate of the drug is probably low.
While FTR1335 had good antifungal properties in vitro, there was a large difference between the effective concentrations that were required for enzyme inhibition and fungal growth inhibition (0.49 nM and 0.78 mM, respectively). One possible explanation is that FTR1335 has a low ability to enter the cell, although it is unclear how many Nmt molecules must be deactivated before growth is inhibited. The permeation of most drugs across the cell membrane by passive diffusion or via a transporter is a critical step in the interaction of a drug with its cellular target and can influence its overall efficacy. Increased antifungal activity requires drug interaction with a transporter to increase the intracellular concentration. For example, the compound caspofungin, was demonstrated to be taken up by a high-affinity transpoter. 28) FTR1335 is reminiscent of the benzofuran derivative RO-09-4879 in that both compounds inhibit CaNmt activity through binding to the peptide-binding site of CaNmt, and have similar antifungal spectra. However RO-09-4879 exhibited lower MIC values rather than those of FTR1335 against some isolates, although the CaNmt IC 50 of FTR1335 was lower than that of RO-09-4879. In particular, a big difference in the MIC values against C. parapsilosis was observed. At present we do not know the reason for that. The Nmt sequence of C. parapsilosis, which has not been revealed yet, may differ greatly from those of other species. Furthermore RO-09-4879 may has another target in that species. In addition, this observation may reflect the difference in the ability of the compounds to permeate the cell membrane.
In conclusion, the results of this study strongly suggest that FTR1335 is a suitable platform for a directed-synthesis program aimed at developing novel antifungal agents, as the benzothiazole structure offers the most promise in terms of selectivity and fungicidal activity. Future studies will continue to optimize this compound and to determine its in vivo therapeutic potential.
